Neoadjuvant Chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for High risk Adult Soft Tissue Sarcomas


To define efficacy of pre-operative chemotherapy in down staging of advanced non-round cell soft tissue sarcomas. From Sep 2002 to Dec 2005, 70 patients were treated by Ifosfamid, MESNA, cisplatin, adriamycin, mitomycin and subsequent surgery. Postoperatively, patients received radiotherapy in cases of microscopically incomplete resection or local recurrence. The median age of the patients was 34 years and the median tumor size was 14 cm. According to AJCC classification 46 patients had stage 3 and 24 had stage 4 diseases. The most common subtypes were MFH and leiomyosarcoma. The most common sites of tumors were lower extremity and trunk. Toxicity grades three or higher consisted of nausea, Leucopenia and infection. About 50% of the patients received G-CSF. Response to chemotherapy was assessable in 63 patients; 9 patients achieved complete response and 16 showed partial response. Disease progressed in 8 and did not change in 37. The best response was seen with MFH, fibrosarcoma and synovial sarcoma. After chemotherapy seventy percent of patients underwent complete surgery. Disease relapsed in 41 patients and twenty two patients died of metastasis. Median survival of patients was 30 months. IMAP plus G-CSF is safe and effective as preoperative chemotherapy in some subtypes of sarcomas, although the metastasis problem has not been eliminated.

Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005; 10(10): 833-41.

Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000; 1: 75-85.

Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13(3): 610-30.

Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. AnnOncol 2004; 15(11): 1667-72.

Raafat J, Sadighi S. Primary adult soft tissue sarcoma in Iran: Multivariate analysis of short and long- term survival. Cancer Bull 2006; 1(1): 5-11.

Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11(7): 1269-75.

Greene FL, Page DL. Fleming ID, Fritz AG, Balch CM. Haller DG, et al, editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.

World Health Organization Handbook for Reporting Results of Cancer Treatment [Online]. Geneva: 1979; Available from: URL:

Cancer Therapy Evaluation Program (CTEP), Common toxicity criteria. Version 2. Bethesda: National Cancer Institute (NCI), 1998.

Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86(10): 2034-7.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20(12): 2824-31.

Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, et al. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 2004; 100(7): 1498-506.

Raut CP, Pisters PW. Retroperitoneal sarcomas: Combined-modality treatment approaches. J Surg Oncol 2006; 94(1): 81-7.

Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, et al. Phase I trial of preoperative doxorubicinbasedconcurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 2004; 22(16): 3375-80.

IssueVol 47, No 2 (2009) QRcode
Soft tissue sarcoma neoadjuvant surgery chemotherapy

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Mohagheghi MA, Sadighi S, Raafat J, Mosavi-Jarrahi AR, Seddigh Z, Ghaemi M. Neoadjuvant Chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for High risk Adult Soft Tissue Sarcomas. Acta Med Iran. 1;47(2):133-138.